Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients

Psychopharmacology

Volumn 131, Issue 2, 1997, Pages 174-179

  Andreassen, Ole A ^a,b   MacEwan, Tom ^c   Gulbrandsen, Anne Karin ^a   McCreadie, Robin G ^c   Steen, Vidar M ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c Crichton Royal Hospital   (United Kingdom)

Author keywords

Akathisia; Anti psychotic drugs; CYP2D6 genotype; Motor side effects; Parkinsonism; Poor metabolizer; Schizophrenia; Tardive dyskinesia

Indexed keywords

CYTOCHROME P450; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ALLELE; ARTICLE; DRUG METABOLISM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSONISM; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PHENOTYPE; SCHIZOPHRENIA;

EID: 0030910635     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050281     Document Type: Article

References (44)

1. Agundez JAG, Jimenez-Jimenez FJ, Luengo A, Bernal ML, Molina JA, Ayuso L, Vazquez A, Parra J, Duarte J, Coria F, Ladero JM, Alvarez JC, Benitez J (1995) Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 57:291-298
2. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (3rd ednm revised) (DSM-III-R). American Psychiatric Association, Washington, D.C.
3. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR (1992) Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 339:1017-1018
4. Arthur H, Dahl ML, Siwers B, Sjöqvist F (1995) Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 15:211-216
5. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
6. Barron ET, McCreadie RG (1983) One year follow-up of tardive dyskinesia. Br J Psychiatry 143:423-424
7. Bergen JA, Fyland EA, Campbell JA, Jenkings P, Kellehear K, Richards A, Beumont PJV (1989) The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry 154:523-528
8. Bertilsson L, Mellström B, Sjöqvist F, Mårtensson B, Åsberg M (1981) Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet i:560-561
9. Brandon S, McClelland HA, Protheroe C (1971) A study of facial dyskinesia in a mental hospital population. Br J Psychiatry 118: 171-184
10. Brøsen K, Gram LF (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36:537-547
11. Chakos MH, Alvir JMJ, Woerner MG, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane JM, Borenstein M, Lieberman JA (1996) Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 53:313-319
12. Cholerton S, Daly AK, Idle JR (1992) The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13:434-439
13. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201
14. Evert B, Griese EU, Eichelbaum M (1994a) Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics 4:271-274
15. Evert B, Griese EU, Eichelbaum M (1994b) A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn-Schmiedeberg's Arch Pharmacol 350:434-439
16. Gardos G, Cole JO, Haskell D, Marby D, Paine SS, Moore P (1988) The natural history of tardive dyskinesia. J Clin Psychopharmacol [8 suppl.]:31-37
17. Jeste DV, Wyatt RJ (1982) Understanding and treating tardive dyskinesia. Guilford Press, New York
18. Johnson GFS, Hunt GE, Rey JM (1982) Incidence and severity of tardive dyskinesia increase with age. Arch Gen Psychiatry 39:486
19. Kane JM (1995) Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 1485-1495
20. Kroemer HK, Eichelbaum M (1995) It's the genes, stupid. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56:2285-2298
21. Kurth MC, Kurth JH (1993) Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 48:166-168
22. McCreadie RG (1982) The Nithsdale schizophrenia survey. I. Psychiatric and social handicaps. Br J Psychiatry 140:582-586
23. McCreadie RG, Barron ET, Winslow GS (1982) The Nithsdale schizophrenia survey. II. Abnormal movements. Br J Psychiatry 140:587-590
24. McCreadie RG, Robertson LJ, Wiles DH (1992) The Nithsdale schizophrenia surveys. IX. Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels. Br J Psychiatry 161: 793-799
25. McCreadie RG, MacDonald E, Wiles D, Campbell G, Paterson JR (1995) The Nithsdale schizophrenia surveys. XIV. Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects. Br J Psychiatry 167:610-617
26. McGuffin P, Farmer AE, Harvey I (1991) A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system. Arch Gen Psychiatry 48:764-770
27. Morgenstern H, Glazer WH (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Arch Gen Psychiatry 50:723-733
28. Muscettola G, Pampailona S, Barbato G, Casiello M, Bollini P (1993) Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand 87:29-36
29. Richardson MA, Craig TJ (1982) The coexistence of parkinsonism-like symptoms and tardive dyskinesia. Am J Psychiatry 139: 341-343
30. Robinson ADT, McCreadie RG (1986) The Nithsdale schizophrenia survey. V. Follow-up of tardive dyskinesia at 3 1/2 years. Br J Psychiatry 149:621-623
31. Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JMJ, Bergmann KJ, Blank K, Koblenzer J, Kahaner K (1991) Prospective study of tardive dyskinesia incidence in the elderly. JAMA 266:2402-2406
32. Sandy MS, Armstrong M, Tanner CM, Daly AK, Di Monte DA, Langston JW, Idle JR (1996) CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology 47:225-230
33. Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487
34. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 [suppl.]:11-19
35. Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Maranganore DM, Sturman SG, Schapira AHV, Williams AC, Spurr NK, Wolf CR (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339:1375-1377
36. Smith JM, Baldessarini RJ (1980) Changes in prevalence, seventy and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 37:1368-1373
37. Spina E, Ancione M, Di Rosa AE, Meduri M, Caputi AP (1992a) Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol 42:347-348
38. Spina E, Campo GM, Calandra S, Caputi AP, Carrillo JA, Benitez J (1992b) Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients. Pharmacol Res 25:43-50
39. Steen VM, Andreassen OA, Daly AK, Tefre T, Børresen AL, Idle JR, Gulbrandsen AK (1995) Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5:215-223
40. US Department of Health, Education & Welfare (1976) Abnormal involuntary movements scale. In: Guy W (ed) ECDEU assessment manual. US Department of Health, Education & Welfare, Rockville, Md.
41. Vallada H, Collier D, Dawson E, Owen M, Nanko S, Murray R, Gill M (1992) Debrisoquine 4-hydroxylase (CYP2D6) locus and possible susceptibility to schizophrenia. Lancet 340:181-182
42. Weinhold P, Wegner JT, Kane JM (1981) Familial occurence of tardive dyskinesia. J Clin Psychiatry 42:165-166
43. World Health Organization (1978) Mental disorders. Glossary and guide to their classification in accordance with the ninth revision of the international classification of diseases. World Health Organization, Geneva, Switzerland
44. Yassa R, Ananth J (1981) Familial tardive dyskinesia. Am J Psychiatry 138:1618-1619